Steroids in Fulminant Hepatitis A in the Pediatric Age Group
Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group
Sponsor: National Liver Institute, Egypt
Listed as NCT02375867, this PHASE4 trial focuses on Fulminant Hepatic Failure and remains completed. Sponsored by National Liver Institute, Egypt, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Apr 2017 — Sep 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Liver Institute, Egypt
- Quesna Central Hospital, Ministry Of Health, Egypt
For direct contact, visit the study record on ClinicalTrials.gov .